The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia

Blood Reviews

Volumn 26, Issue SUPPL.1, 2012, Pages

  Thein, Swee Lay ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Beta thalassemia; Fetal hemoglobin; HbF induction

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARGININE BUTYRATE; AZACITIDINE; CYTOTOXIC AGENT; ERYTHROPOIETIN; FERRITIN; GAMMA GLOBIN; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; ISOBUTYRIC ACID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; BETA THALASSEMIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHROBLAST; ERYTHROID CELL; FERRITIN BLOOD LEVEL; GENE EXPRESSION; GENE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; NON TRANSFUSIONAL DEPENDENT THALASSEMIA; PRIORITY JOURNAL; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE;

BETA-THALASSEMIA; BLOOD TRANSFUSION; FETAL HEMOGLOBIN; HUMANS;

EID: 84861412448     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/S0268-960X(12)70011-5     Document Type: Article

References (63)

1. Weatherall DJ The thalassaemias. Br Med J 1997, 314(7095):1675-1678.
2. Thein SL Pathophysiology of beta thalassemia - a guide to molecular therapies. Hematology Am Soc Hematol Educ Program 2005, 31-37.
3. Thein SL, Menzel S Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009, 145(4):455-467.
4. Muncie HL, Campbell J Alpha and beta thalassemia. Am Fam Physician 2009, 80(4):339-344.
5. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 2008, 105(5):1620-1625.
6. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A 2007, 104(27):11346-11351.
7. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007, 39(10):1197-1199.
8. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322(5909):1839-1842.
9. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006, 108(3):1077-1083.
10. Wahlberg K, Jiang J, Rooks H, et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 2009, 114(6):1254-1262.
11. Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 2009, 41(11):1191-1198.
12. Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010, 42(3):210-215.
13. Menzel S, Jiang J, Silver N, et al. The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans. Blood 2007, 110(10):3624-3626.
14. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009, 41(11):1182-1190.
15. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010, 42(9):801-805.
16. Giardine B, Borg J, Higgs DR, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet 2011, 43(4):295-301.
17. Siatecka M, Sahr KE, Andersen SG, Mezei M, Bieker JJ, Peters LL Severe anemia in the Nan mutant mouse caused by sequence-selective disruption of erythroid Krüppel-like factor. Proc Natl Acad Sci U S A 2010, 107(34):15151-15156.
18. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010, 42(9):742-744.
19. Miller IJ, Bieker JJ A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol 1993, 13(5):2776-2786.
20. Gallo E, Massaro P, Miniero R, David D, Tarella C The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia. Br J Haematol 1979, 41(2):211-221.
21. Perrine SP Fetal globin induction - can it cure beta thalassemia?. Hematology Am Soc Hematol Educ Program 2005, 38-44.
22. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia. Blood 2012, 119(2):364-367.
23. Atweh GF, Schechter AN Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001, 8(2):123-130.
24. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 2001, 97(10):3259-3267.
25. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984, 74(2):652-656.
26. Skarpidi E, Cao H, Heltweg B, et al. Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Exp Hematol 2003, 31(3):197-203.
27. Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005, 105(4):1807-1809.
28. Olivieri NF, Saunthararajah Y, Thayalasuthan V, et al. A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood 2011, 118(10):2708-2711.
29. Rachmilewitz EA, Aker M The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci 1998, 850:129-138.
30. Rigano P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol 2010, 151(5):509-515.
31. Bohacek R, Boosalis MS, McMartin C, Faller DV, Perrine SP Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and " PSEUDO" receptor models. Chem Biol Drug Des 2006, 67(5):318-328.
32. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 2002, 100(13):4640-4648.
33. Cao H, Jung M, Stamatoyannopoulos G Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo. Exp Hematol 2005, 33(12):1443-1449.
34. Fibach E, Bianchi N, Borgatti M, et al. Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients. Eur J Haematol 2006, 77(5):437-441.
35. Rodrigue CM, Arous N, Bachir D, et al. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br J Haematol 2001, 113(2):500-507.
36. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008, 118(1):248-258.
37. Aguilar-Lopez LB, Delgado-Lamas JL, Rubio-Jurado B, Perea FJ, Ibarra B Thalidomide therapy in a patient with thalassemia major. Blood Cells Mol Dis 2008, 41(1):136-137.
38. Xu J, Peng C, Sankaran VG, et al. Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing. Science 2011, 334(6058):993-996.
39. Borg J, Patrinos GP, Felice AE, Philipsen S Erythroid phenotypes associated with KLF1 mutations. Haematologica 2011, 96(5):635-638.
40. Liu P, Keller JR, Ortiz M, et al. Bcl11a is essential for normal lymphoid development. Nat Immunol 2003, 4(6):525-532.
41. Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 2010, 107(28):12617-12622.
42. Hajjar FM, Pearson HA Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 1994, 125(3):490-492.
43. Zeng YT, Huang SZ, Ren ZR, et al. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol 1995, 90(3):557-563.
44. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood 1996, 87(3):887-892.
45. Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol 2005, 131(3):378-388.
46. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 1998, 850:120-128.
47. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapyin beta-thalassemia. Am J Hematol 2008, 83(5):366-370.
48. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia - a promising therapy. Ann Hematol 2005, 84(7):441-446.
49. Karimi M, Darzi H, Yavarian M Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol 2005, 27(7):380-385.
50. Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med 1982, 307(24):1469-1475.
51. Dunbar C, Travis W, Kan YW, Nienhuis A 5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies. Br J Haematol 1989, 72(3):467-468.
52. Lowrey CH, Nienhuis AW Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Engl J Med 1993, 329(12):845-848.
53. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 1995, 85(1):43-49.
54. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl JMed 1993, 328(2):81-86.
55. Perrine SP, Castaneda SA, Boosalis MS, White GL, Jones BM, Bohacek R Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress. Ann N Y Acad Sci 2005, 1054:257-265.
56. Cappellini MD, Graziadei G, Ciceri L, al E Oral isobutyramide therapy in patients with thalassemia intermedia: Results of a phase II open study. Blood Cells Mol Dis 2000, 26:105-111.
57. Reich S, Buhrer C, Henze G, et al. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood 2000, 96(10):3357-3363.
58. Bourantas K, Economou G, Georgiou J Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. Eur J Haematol 1997, 58(1):22-25.
59. Nisli G, Kavakli K, Vergin C, Oztop S, Cetingul N Recombinant human erythropoietin trial in thalassemia intermedia. J Trop Pediatr 1996, 42(6):330-334.
60. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol 1997, 98(4):199-203.
61. Chaidos A, Makis A, Hatzimichael E, et al. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematol 2004, 111(4):189-195.
62. Singer ST, Kuypers F, Coates TD, al E The effect of single and combination drug therapy on previously transfused E/beta-thalassemia patients: Implications on decision making for therapy. Blood 2002, 100:119a-120a.
63. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997, 350(9076):491-492.